A newly identified COVID-19 variant—referred to as “Cicada”—is being tracked across a growing number of U.S. states, according to the Centers for Disease Control and Prevention. While the variant currently represents a small share of domestic cases, its presence is increasing and drawing attention from public health officials.
- The variant (BA.3.2) has been detected in multiple U.S. states through routine surveillance
- It remains a small percentage of total U.S. COVID-19 cases
- In parts of Europe, it has grown to account for up to 30% of cases
- Health officials are monitoring its potential to evade immunity from prior infection or vaccination
At this stage, there is no indication that the variant is driving widespread surges in the U.S., but its growth internationally underscores the importance of continued monitoring and data analysis.
For healthcare providers, this serves as a reminder that COVID-19 remains an evolving concern. Staying informed on variant trends, maintaining surveillance protocols, and ensuring readiness for potential shifts in case patterns will be key to ongoing patient care and operational planning.